terican

Last verified · v1.0

Calculator · health

Gabapentin Dosage Calculator

Estimate gabapentin daily dose by weight, indication, and renal function using automatic Cockcroft-Gault creatinine clearance adjustment.

FreeInstantNo signupOpen source

Inputs

Recommended Daily Dose

—

Explain my result

0/3 free

Get a plain-English breakdown of your result with practical next steps.

Recommended Daily Dose—mg/day

The formula

How the
result is
computed.

How the Gabapentin Dosage Calculator Works

The gabapentin dosage calculator estimates a patient's daily dose using three core components: body weight, clinical indication, and a renal adjustment factor derived from the Cockcroft-Gault creatinine clearance equation. The foundational formula is:

Daily Dose (mg) = Weight (kg) × Dose (mg/kg/day) × Renal Adjustment Factor

This weight-based approach is especially critical for pediatric patients and adults with impaired renal function, since gabapentin is eliminated almost exclusively by the kidneys. According to the NEURONTIN FDA Prescribing Information, dose reductions are required whenever creatinine clearance (CrCl) falls below 60 mL/min.

Understanding the Input Variables

Patient Weight

Weight drives the per-kilogram dose calculation. The calculator accepts both kilograms and pounds, automatically converting pounds to kilograms (1 lb = 0.4536 kg) before computing the dose. For obese patients, clinical practice often favors adjusted body weight over total body weight to prevent supratherapeutic plasma concentrations.

Clinical Indication

Target dose ranges differ significantly by indication:

  • Epilepsy (adults): 900–3,600 mg/day in three divided doses
  • Postherpetic Neuralgia: 1,800–3,600 mg/day, titrated over 3 days (300 mg Day 1, 600 mg Day 2, 900 mg Day 3)
  • Neuropathic Pain: 300–3,600 mg/day, titrated to clinical response
  • Pediatric Epilepsy (ages 3–12): 10–15 mg/kg/day initially, maximum 25–40 mg/kg/day in three divided doses

Renal Adjustment Factor (Cockcroft-Gault Method)

Because gabapentin undergoes no hepatic metabolism and is cleared entirely by the kidneys, renal function is the primary determinant of dose adjustment. The calculator applies the validated Cockcroft-Gault equation to estimate creatinine clearance:

CrCl (mL/min) = [(140 - Age) × Weight (kg)] ÷ (72 × Serum Creatinine) × 0.85 (if female)

A landmark pharmacokinetic review published in BMC Nephrology on rational gabapentin dosing in chronic kidney disease (PMC5291335) establishes the following CrCl-based dose adjustment tiers, which this calculator applies automatically:

  • CrCl ≥ 60 mL/min: Full dose — 300–1,200 mg three times daily (900–3,600 mg/day)
  • CrCl 30–59 mL/min: Reduce to 200–700 mg twice daily (400–1,400 mg/day)
  • CrCl 15–29 mL/min: Reduce to 200–700 mg once daily (200–700 mg/day)
  • CrCl < 15 mL/min: Reduce to 100–300 mg once daily
  • Hemodialysis: 125–350 mg supplemental dose after each 4-hour dialysis session

Worked Calculation Example

Consider a 68-year-old female weighing 70 kg with a serum creatinine of 1.8 mg/dL being treated for postherpetic neuralgia.

  1. Estimate CrCl: [(140 - 68) × 70] ÷ (72 × 1.8) × 0.85 = 5,040 ÷ 129.6 × 0.85 ≈ 33 mL/min
  2. Select dose tier: CrCl 30–59 mL/min → maximum 700 mg twice daily (1,400 mg/day)
  3. Titrate from initiation: Begin at 100–300 mg twice daily and increase over 1–2 weeks as tolerated toward the target range.

Special Populations and Drug Interactions

Gabapentin dosing must account for patient-specific factors beyond basic renal function. Elderly patients frequently experience enhanced CNS sensitivity to gabapentin, requiring conservative starting doses (100–300 mg once daily) with slower titration schedules even when renal function is preserved. Pregnant patients require individualized risk-benefit assessment, as gabapentin crosses the placental barrier; however, no definitive teratogenic risk has been established in human studies. Patients with hepatic impairment require no dose adjustment since gabapentin undergoes minimal hepatic metabolism, but close monitoring is warranted when combined with other CNS depressants.

Co-administration with opioids substantially increases the risk of respiratory depression, sedation, and overdose-related mortality. This interaction is particularly significant in patients with sleep apnea or chronic obstructive pulmonary disease. Similarly, benzodiazepines, barbiturates, and other central nervous system depressants potentiate gabapentin's sedative and respiratory effects. Morphine administration increases gabapentin plasma concentrations, requiring coordinated dose adjustments across both medications.

Titration Protocols and Clinical Monitoring

Most gabapentin therapies employ gradual titration schedules to minimize adverse effects while optimizing efficacy. Typical titration begins at 300 mg daily (100 mg three times daily) and increases by 300 mg daily every 1–7 days based on tolerability and clinical response. Seizure control or pain reduction often requires 1–2 weeks to manifest fully; premature dose escalation can amplify side effects without improving outcomes. Patients should be instructed to report persistent sedation, ataxia, dizziness, or mood changes within the first two weeks of therapy initiation. Therapeutic drug monitoring through plasma level measurement is not routinely indicated, as gabapentin concentrations do not reliably predict clinical response or toxicity.

Clinical Considerations and Disclaimer

The gabapentin dosage calculator provides an evidence-based starting estimate. Prescribers must individualize therapy based on patient tolerability, concurrent CNS depressants, comorbidities, and observed clinical response. Gabapentin carries a documented risk of respiratory depression when co-administered with opioids, a concern highlighted in the CDC Clinical Practice Guideline for Prescribing Opioids for Pain. This tool does not replace professional medical judgment. Always consult the current FDA prescribing information and institutional protocols before initiating or modifying gabapentin therapy.

Reference

Frequently asked questions

What is the standard starting dose of gabapentin for adults?
For postherpetic neuralgia, gabapentin is initiated at 300 mg on Day 1, increased to 600 mg on Day 2, and reaches 900 mg on Day 3. Maintenance doses range from 1,800 to 3,600 mg daily in three divided doses. For epilepsy adjunctive therapy, effective doses range from 900 to 3,600 mg per day divided into three equal doses, titrated based on tolerability and seizure control over several weeks.
How does kidney disease affect gabapentin dosing?
Kidney disease significantly reduces gabapentin clearance because the drug is eliminated almost entirely by renal excretion without hepatic metabolism. Patients with a creatinine clearance of 30–59 mL/min should receive no more than 1,400 mg per day in two divided doses. Those with CrCl below 15 mL/min require only 100–300 mg once daily. Patients on hemodialysis need a supplemental dose of 125–350 mg after every 4-hour dialysis session to replace drug removed during filtration.
What is the maximum safe daily dose of gabapentin?
The FDA-approved maximum daily dose of gabapentin is 3,600 mg per day for adults with normal renal function (CrCl ≥ 60 mL/min), divided into three doses of 1,200 mg each. This ceiling reflects both efficacy plateau data and tolerability limits established in pivotal clinical trials. Exceeding 3,600 mg/day rarely produces additional therapeutic benefit and substantially increases adverse effects, including somnolence reported in up to 19.3% of patients, dizziness, and ataxia.
How is gabapentin dosed in pediatric patients with epilepsy?
For children aged 3 to 12 years with partial seizures, gabapentin is initiated at 10 to 15 mg per kilogram per day divided into three doses, then titrated to effective levels over approximately 3 days. Maximum target doses are 40 mg/kg/day for children aged 3–4 years and 25–35 mg/kg/day for those aged 5 years and older. Children over 12 years follow standard adult dosing schedules. All pediatric doses should be rounded to the nearest available capsule or tablet strength.
Why is gabapentin typically prescribed three times a day rather than once or twice daily?
Gabapentin has a short elimination half-life of approximately 5 to 7 hours in adults with normal renal function, requiring three-times-daily dosing to maintain stable therapeutic plasma concentrations throughout the day. Once-daily dosing creates peak-to-trough fluctuations that reduce efficacy and amplify side effects at peak concentrations. Twice-daily schedules are reserved for renally impaired patients where the prolonged half-life from reduced clearance compensates for the less frequent administration interval.
What symptoms suggest a gabapentin dose is too high?
Signs of excessive gabapentin dosing include severe drowsiness, ataxia (loss of balance and coordination), slurred speech, diplopia (double vision), and — especially when combined with opioids or benzodiazepines — respiratory depression. FDA label clinical trial data report dizziness in up to 28% and ataxia in up to 12.5% of gabapentin-treated adults. Any acute worsening of these symptoms warrants immediate contact with the prescribing clinician for dose reduction, schedule adjustment, or discontinuation.